Moderna's stock surged 177% on August 19 after its personalized mRNA melanoma vaccine with Merck delayed recurrence in over 1,000 high-risk patients. This follows the August 7 FDA approval of its mRNA flu vaccine for older adults. Watch for full data on the melanoma vaccine and its market entry.